These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28924290)

  • 21. Cytogenetic Abnormalities In Acute Myeloid Leukaemia Patients.
    Shaikh MR; Haider G; Memon P; Rahool R; Nouman M; Beg S; Meher K; Zahoor S; Sami A; Pavan B
    J Ayub Med Coll Abbottabad; 2020; 32(1):33-37. PubMed ID: 32468751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy-related myelodysplastic syndrome/acute myeloid leukemia with del(7)(q22) in a patient with de novo AML.
    Kim YG; Cho SY; Park TS; Oh SH; Yoon HJ
    Ann Clin Lab Sci; 2011; 41(1):79-83. PubMed ID: 21325260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts.
    Mangaru Z; Shetty S; Visconte V; Liu HD; Rogers HJ
    Am J Hematol; 2016 Jun; 91(4):E273-4. PubMed ID: 26719044
    [No Abstract]   [Full Text] [Related]  

  • 24. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of cytogenetic abnormalities in acute myeloid leukaemia.
    Harani MS; Adil SN; Kakepoto GN; Khilji Z; Shaikh U; Khurshid M
    J Pak Med Assoc; 2006 Jan; 56(1):9-13. PubMed ID: 16454127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MICM characteristics and typing diagnosis in acute myelogenous leukemia patients (AML-M2) with complex karyotype t (2;21;8)(p12;q22;q22)].
    Ma Y; Tong HX; Deng X; Zhao Y; Liu ZG; Zhang JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):12-6. PubMed ID: 19236738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of acute myelogenous leukemia in patients more than 80 years old].
    Takeyama H; Yamamoto Y; Miyata Y; Yamada H; Watanabe E; Aoki H; Iinuma M
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1089-93. PubMed ID: 9239161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
    Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
    Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic fibrosis with acute myelogenous leukemia.
    Aytaç S; Pekcan S; Doğru D; Dörttepe I; Kara A; Cetin M
    Turk J Pediatr; 2009; 51(3):290-3. PubMed ID: 19817276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia.
    Saini L; Brandwein J; Szkotak A; Ghosh S; Sandhu I
    Leuk Lymphoma; 2018 Jan; 59(1):121-128. PubMed ID: 28540755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
    Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
    J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Percutaneous coronary intervention in a patient with acute myeloid leukemia].
    Staib P; Forsch S; Niedeggen A; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1092-5. PubMed ID: 22588653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).
    Wang H; Yang W; Shao H; Zhang J; Qi L; Liao A; Li Y; Liu Z
    Cancer Genet Cytogenet; 2009 Jan; 188(2):95-8. PubMed ID: 19100512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].
    Li HY; Yue H; Wei XD; Zhu XH; Zhang YL; Zhang LN; Liu YY; Wang P; Fang BJ; Li YF; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):110-2. PubMed ID: 18681312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.